Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients

Introduction: Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR overexpression and mutation in NSCLC can be determined using radiolabeled EGFR TKI PET/CT. However, recent research has shown a si...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartelink, I. H., van de Stadt, E. A., Leeuwerik, A. F., Thijssen, V. L. J. L., Hupsel, J. R. I., van den Nieuwendijk, J. F., Bahce, I., Yaqub, M., Hendrikse, N. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315544/
https://www.ncbi.nlm.nih.gov/pubmed/35890095
http://dx.doi.org/10.3390/ph15070796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315544/
https://www.ncbi.nlm.nih.gov/pubmed/35890095
http://dx.doi.org/10.3390/ph15070796

Ejemplares similares